Standout Papers

Rituximab chimeric anti-CD20 monoclonal antibody therapy... 1980 2026 1995 2010 2.1k
  1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (1998)
    Peter McLaughlin, A.J. Grillo-López et al. Journal of Clinical Oncology
  2. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells (1996)
    Frank J. Hsu, Claudia Benike et al. Nature Medicine
  3. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997)
    David G. Maloney, Antonio J Grillo-López et al. Blood
  4. Two populations of Ia-like molecules on a human B cell line. (1980)
    L A Lampson, Ronald Levy The Journal of Immunology
  5. Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma (2003)
    Wen‐Kai Weng, Ronald Levy Journal of Clinical Oncology
  6. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma (2010)
    Mark P. Chao, Ash A. Alizadeh et al. Cell
  7. Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody (1982)
    Richard Miller, David G. Maloney et al. New England Journal of Medicine
  8. Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes (2004)
    Izidore S. Lossos, Debra K. Czerwinski et al. New England Journal of Medicine
  9. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma (1994)
    DG Maloney, J. Rosenberg et al. Blood
  10. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia (2009)
    Jonathan W. Friedberg, Jeff P. Sharman et al. Blood
  11. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. (1997)
    DG Maloney, A.J. Grillo-López et al. Journal of Clinical Oncology
  12. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment (2000)
    Thomas A. Davis, Antonio J Grillo-López et al. Journal of Clinical Oncology
  13. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK (2015)
    Idit Sagiv-Barfi, Holbrook E. Kohrt et al. Proceedings of the National Academy of Sciences
  14. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016)
    Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research

Immediate Impact

20 by Nobel laureates 22 from Science/Nature 91 standout
Sub-graph 1 of 21

Citing Papers

The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
Harnessing innate immunity in cancer therapy
2019 StandoutNature
20 intermediate papers

Works of Ronald Levy being referenced

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
2013
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
2010 Standout
and 27 more

Author Peers

Author Last Decade Papers Cites
Ronald Levy 20232 11758 12628 14199 687 44.2k
Thomas A. Waldmann 27606 6624 4829 10544 573 47.0k
Klaus Rajewsky 41459 11278 8333 11187 502 76.4k
Louis M. Staudt 11150 1929 10568 9282 285 34.0k
Riccardo Dalla‐Favera 12854 1579 14994 14258 299 39.9k
Volker Diehl 6166 3854 17115 13770 688 30.6k
Brunangelo Falini 7782 1834 15273 10587 382 32.4k
Jerome Ritz 18842 3315 4476 9935 599 35.8k
Stuart F. Schlossman 22004 10210 3117 6374 336 35.3k
Elaine S. Jaffe 14976 2491 37023 27737 712 61.7k
Herman Waldmann 22115 6275 3218 5311 537 36.1k

All Works

Loading papers...

Rankless by CCL
2026